NASDAQ:ICLR - Icon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$138.02 +0.74 (+0.54 %)
(As of 05/22/2019 08:55 AM ET)
Previous Close$137.28
Today's Range$136.31 - $139.40
52-Week Range$118.10 - $155.33
Volume251,753 shs
Average Volume301,618 shs
Market Capitalization$7.45 billion
P/E Ratio21.94
Dividend YieldN/A
Beta0.62
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$7.6381 per share
Book Value$26.35 per share

Profitability

Net Income$322.66 million

Miscellaneous

Employees13,670
Market Cap$7.45 billion
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) released its quarterly earnings results on Wednesday, May, 1st. The medical research company reported $1.63 EPS for the quarter, topping the Zacks' consensus estimate of $1.60 by $0.03. The medical research company had revenue of $674.85 million for the quarter, compared to analyst estimates of $668.93 million. Icon had a return on equity of 25.71% and a net margin of 12.56%. Icon's revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.44 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY19 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of $6.75-6.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.83. The company issued revenue guidance of $2.76-2.84 billion, compared to the consensus revenue estimate of $2.79 billion.

What price target have analysts set for ICLR?

11 brokers have issued 12-month target prices for Icon's shares. Their forecasts range from $136.00 to $168.00. On average, they anticipate Icon's share price to reach $153.00 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

News coverage about ICLR stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Icon earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), Procter & Gamble (PG), Amgen (AMGN), Alibaba Group (BABA), Johnson & Johnson (JNJ), Visa (V), Adobe (ADBE) and Netflix (NFLX).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (6.43%), WCM Investment Management LLC (6.15%), Renaissance Technologies LLC (4.12%), Acadian Asset Management LLC (3.98%), Boston Partners (2.79%) and Pendal Group Ltd (2.61%).

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Wellington Management Group LLP, Blackcrane Capital LLC, New York State Common Retirement Fund, Wells Fargo & Company MN, Northern Trust Corp, Wasatch Advisors Inc. and FMR LLC.

Which institutional investors are buying Icon stock?

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Comgest Global Investors S.A.S., Boston Partners, Morgan Stanley, Ellis Investment Partners LLC, Ellis Investment Partners LLC, Charles Schwab Investment Management Inc. and Marshall Wace North America L.P..

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $138.02.

How big of a company is Icon?

Icon has a market capitalization of $7.45 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com/.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  459 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  827
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel